Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 18;19(3):e0298163. doi: 10.1371/journal.pone.0298163

Momordica charantia fruit reduces plasma fructosamine whereas stems and leaves increase plasma insulin in adult mildly diabetic obese Göttingen Minipigs

Sietse Jan Koopmans 1,*, Gisabeth Binnendijk 1, Allison Ledoux 2, Young Hae Choi 2,3, Jurriaan J Mes 4, Xiaonan Guan 5, Francesc Molist 5, Tâm Phạm Thị Minh 6, Nikkie van der Wielen 7
Editor: Ahmed E Abdel Moneim8
PMCID: PMC10947704  PMID: 38498469

Abstract

Background

Traditionally Momordica charantia (Bitter gourd) is known for its blood glucose lowering potential. This has been validated by many previous studies based on rodent models but human trials are less convincing and the physiological mechanisms underlying the bioactivity of Bitter gourd are still unclear. The present study compared the effects of whole fruit or stems-leaves from five different Bitter gourd cultivars on metabolic control in adult diabetic obese Göttingen Minipigs.

Methods

Twenty streptozotocin-induced diabetic (D) obese Minipigs (body weight ~85 kg) were subdivided in mildly and overtly D pigs and fed 500 g of obesogenic diet per day for a period of three weeks, supplemented with 20 g dried powdered Bitter gourd or 20 g dried powdered grass as isoenergetic control in a cross-over, within-subject design.

Results

Bitter gourd fruit from the cultivars “Palee” and “Good healthy” reduced plasma fructosamine concentrations in all pigs combined (from 450±48 to 423±53 and 490±50 to 404±48 μmol/L, both p<0.03, respectively) indicating improved glycemic control by 6% and 17%. These effects were statistically confirmed in mildly D pigs but not in overtly D pigs. In mildly D pigs, the other three cultivars of fruit showed consistent numerical but no significant improvements in glycemic control. The composition of Bitter gourd fruit was studied by metabolomics profiling and analysis identified three metabolites from the class of triterpenoids (Xuedanoside H, Acutoside A, Karaviloside IX) that were increased in the cultivars “Palee” (>3.9-fold) and “Good healthy” (>8.9-fold) compared to the mean of the other three cultivars. Bitter gourd stems and leaves from the cultivar “Bilai” increased plasma insulin concentrations in all pigs combined by 28% (from 53±6 to 67±9 pmol/L, p<0.03). The other two cultivars of stems and leaves showed consistent numerical but no significant increases in plasma insulin concentrations. The effects on plasma insulin concentrations were confirmed in mildly D pigs but not in overtly D pigs.

Conclusions

Fruits of Bitter gourd improve glycemic control and stems-leaves of Bitter gourd increase plasma insulin concentrations in an obese pig model for mild diabetes. The effects of Bitter gourd fruit on glycemic control seem consistent but relatively small and cultivar specific which may explain the varying results of human trials reported in the literature.

Introduction

Momordica charantia, also known as Bitter melon, Sopropo, Karela or Bitter gourd is used in folk medicine all over the world as functional food for the treatment of different pathologies, mainly obesity, metabolic syndrome and type 2 diabetes mellitus [1]. All the parts of Bitter gourd are suitable as food or feed ingredient, in particular fruit, stems and leaves [2]. Fruit and leaves of Bitter gourd contain compounds like glycosides, saponins, alkaloids and triterpenes which can lower blood glucose levels but the mode of action is unclear because it consists of an undefined mixture of compounds [3]. Scientific proof for the beneficial effects of Bitter gourd on human metabolism is however not convincing [4]. Several clinical studies in diabetic obese patients have been conducted which suggest an effect on glycemic control but scientific robustness, proper standardization and quality control remain questionable [4]. Standardization of the study design and adherence to the study protocol is more easily achieved in animal studies and these studies showed in general beneficial effects of Bitter gourd on glycemic control [5]. However, the vast majority of these animal studies was conducted in small animals like rodents but large animal models have not been used [5]. Pig models are considered ideal for studies on food and metabolism because nutritional-physiology of pigs and man are similar [6]. Minipig models for the study of human obesity and diabetes are recommended for translational research as discussed in previous reviews [7, 8].

To fill the gap between rodent research and human studies, we have developed an adult streptozotocin-induced diabetic obese Göttingen Minipig model for human obese metabolic syndrome and mild type-2 diabetes based on previous experience [9]. This adult Minipig model expresses a non-growing, yet obese phenotype, and can be used to monitor the effect of functional foods on metabolism. Also feed intake can be accurately standardized to exclude any possible confounding effects of changes in voluntary feed intake on glycemic control. Part of the glycemic lowering effects of Bitter gourd may be caused by a reduction in food intake as induced by the appetite-suppressing effects of the bitter taste [10] and certain satiety-inducing fibre types [11], both hall marks of Bitter gourd fruit. In the present study we aimed for constant feed intake throughout the study, in order to expose the direct mechanistic physiologic and metabolic effects of Bitter gourd on glycemic control in the absence of changes in feed intake. In addition, many different cultivars of Bitter gourd exist and not all cultivars may be equally effective in influencing metabolism and glycemic control in diabetic obese subjects. Therefore, the present study aimed to compare the effects of whole fruit or stems-leaves from five different Bitter gourd cultivars on metabolic control in adult diabetic obese Göttingen Minipigs, while concurrently conducting an in-depth analysis of triterpenoid compounds within these plant samples. The triterpenoid compounds were measured using a metabolomic approach that involved LC/MS-MS analysis, and the results were subjected to identification processes through systematic comparison, including fragment MS analysis, with the Dictionary of Natural Products database.

Materials and Methods

Animals, housing and diet

The performed research is in compliance with the ARRIVE guidelines on animal research [12]. Experimental protocols describing the management, surgical procedures, and animal care were reviewed and approved by the ASG-Wageningen Animal Care and Use Committee (Wageningen, The Netherlands). AVD license number 40100201858.

A total of 24 female Göttingen Minipigs were purchased from Ellegaard, Dalmose, Denmark. Female pigs were chosen because they are more sensitive to metabolic abnormalities than males [13]. Multiparous, non-pregnant sows were used to reflect adult women. Average age and body weight at the start of the experiment was 2–3 years and 30–40 kg. Pigs were group housed (3 to 4 per pen, pen size 6 m2) on straw bedding and were provided with three different toys to play with. The ambient room temperature was 20°C. All pigs were adapted to the light-dark cycle–lights being on from 06:00 to 22:00 h–and feeding was provided from 15:00 to 16:00. Pigs were fed individually 1 meal of 500 g per day of a mild obesogenic diet (Table 1).

Table 1. Ingredients of mild obesogenic diet.

Mild obesogenic diet
Ingredient %
Barley 10
Wheat 8
Soja hulls (crude fibre 32–36%) 36
Potato protein 4
Wheat gluten protein 5
Sucrose 20
Lard 13
Cholesterol 0.5
Limestone CaCO3 (powder) 1.4
Mono-Calcium phosphate 1.8
NaCl 0.6
Premix 2 g/kg 0.2
L-Tryptophan 0.01
Total 100.00

The first week, the sows received 500 g of diet, the second week 1 kg of diet, the third week 1.5 kg of diet and thereafter 2 kg of diet per meal per day. Within five months body weight was increased more than two-fold. At this obese phenotype, meal size was reduced weekly until reaching 500 g of diet per day. Empirically it was found that at a feed intake of 500 g per day, body weight of the obese sows (~85 kg) was stable over time. Energy intake was 2262 kcal (= 9.5 MJ) per day (Table 2) similar to the recommended dietary energy intake for humans (2000–2500 kcal per day). Feed consumption was registered daily by weighing the provided meal and weighing feed refusals. Pigs were weighed once per three weeks.

Table 2. Calculated nutrient composition of the mild obesogenic diet (per 500 g) and supplements per 20 g (grass, Bitter gourd fruit and Bitter gourd stems and leaves).

Mild obesogenic diet (500 grams) Dried grass (20 grams) Dried Bitter gourd fruit (20 grams) Dried Bitter gourd stems and leaves (20 grams)
Dry matter g 463 18.6 19.3 18.1
Crude ash g 29 3.4 2.0 3.5
Crude protein g 65 3.1 4.4 2.9
Crude fat g 69 0.6 1.9 0.5
Crude fibre including non-starch polysaccharides g 137 8.7 10.2 11.1
Sugars g 111 2.5 0.3 0.14
Sugars and starches g 163 2.8 0.8 0.14
Total carbohydrates g 300 11.5 11.0 11.2
Gross energy MJ 9.50 0.30 0.37 0.29

Fruit or stems and leaves from Bitter gourd

Four cultivars of Bitter gourd (Wild-type, HTM 242, Palee and Good healthy) were cultivated outdoors and obtained from Nong Lam University, Ho Chi Minh City, Vietnam. One cultivar of Bitter gourd (Bilai) was cultived in a green house and obtained from Fresh farma, Bleiswijk, The Netherlands. Fruit and/or stems and leaves of these five cultivars were prepared in a dried powdered form. The drying-powdering process for all cultivars was as follows: fresh clean material was cut into pieces (thick: < 5 mm) and placed in an air-vented oven at 60°C for three days until the weight of the material remained constant. The material was turned twice daily to improve drying. The dried material was milled to powder and sealed in plastic bags. Material was stored in the dark at room temperature prior use. Dried powdered grass (Oldambt Crop Driers, ABZ Leusden, The Netherlands) was used as isoenergetic control treatment. Dried powdered grass at an inclusion level of 4% in the pig diet is well tolerated by pigs and macronutrient composition (protein, fat and carbohydrates) of grass [14] was in the range of the composition of Bitter gourd fruit or stems and leaves. Calculated composition of the meals (per 500 g) and the supplements (Bitter gourd or grass) per 20 g is shown in Table 2.

Composition was based on data obtained from the Centraal Veevoeder Bureau 2011, CVB table pigs, Product Board Animal Feed, The Hague, The Netherlands [14]; additional information for dried grass: Oldambt Crop Driers, harvest 2018, ABZ Leusden, The Netherlands; for Bitter gourd fruit: Agro Control, Stichting control in food & flowers, Delftgauw, The Netherlands; for Bitter gourd stems and leaves: Schothorst Feed Research, Lelystad, The Netherlands and from references [1517]. Analyses of residues in dried powdered Bitter gourd by mass spectrometry showed no pesticides or heavy metals above legally-tolerated concentrations. Acetamiprid Q, Azoxystrobine Q, Imidacioprid Q and Cypermethrin Q were below 0.04, 0.05, 0.08 and 0.45 mg/kg and Arsene Q, Cadmium Q, Mercury (hg) Q and Led (Pb) Q were below 0.05, 0.01, 0.01 and 0.03 mg/kg (Agro Control, Stichting control in food & flowers, Delftgauw, The Netherlands).

Induction of diabetes by streptozotocin treatment

Obese Göttingen Minipigs (~ 85 kg) were anesthetized with intramuscular azaperone 2 mg/kg (Stressnil, Janssen, Tilburg, The Netherlands), followed by intravenous thiopental 15 mg/kg (Nesdonal, Rhone Merieux, Lyon, France). A permanent blood vessel catheter (Becton Dickinson, Secalon Seldy, 16 G, polyurethane, Franklin Lakes, NJ, USA) was inserted in the ear vein and fixed firmly to the ear. The catheter was flushed with physiological saline and sealed off with physiological saline containing 5 IU heparin per mL when not in use.

A diabetic state in the pigs was induced by slow injection (over a period of 1 minute) of the pancreatic β-cell cytotoxin streptozotocin (STZ, Enzo Life Sciences, Raamsdonksveer, The Netherlands) in the ear vein after overnight fasting, modified as described previously [9, 18, 19]. STZ was dissolved in 0.1 mol/l Na-citrate, pH 4.5 at a concentration of 1 g per 20 mL and filter-sterilized before use. STZ-injected Minipigs were provided with an afternoon meal to counteract possible hypoglycemia which can occur due to endogenous insulin release by destroyed pancreatic β-cells. Multiple daily injections of STZ are needed to induce post-STZ hyperglycemia (>10 mmol/L) and the number of STZ injections are pig specific (due to inter-animal variation). We chose to use different strategies (based on dose and number of STZ injections) to induce mild or more severe diabetes in pigs:

Strategy 1 (aim to induce mild diabetes): daily repeated STZ (1 g/day) injections were given to 10 Minipigs until reaching a >3-fold increase in fasting blood glucose concentrations. Mean baseline 18-h fasting blood glucose concentrations were 2.8±0.2 mmol/L. Three to 6 injections of STZ per pig were needed to reach a mean fasting blood glucose concentration of 11.4±0.7 mmol/L on the day after the last STZ injection. At 3, 5 and 8 weeks post-STZ treatment, fasting blood glucose concentrations slowly stabilized at 8.5±1.3, 5.9±0.7 and 4.2±0.4 mmol/L, respectively. Twelve weeks post-STZ treatment, at the start of the Bitter gourd trials, fasting plasma glucose concentrations were 4.6±0.5 mmol/L.

Strategy 2 (aim to induce overt diabetes): two injections of STZ (1.5 g on the first day and 3 g on the second day) were given to 9 Minipigs. Mean baseline 18-h fasting blood glucose concentrations were 2.9±0.1 mmol/L. Two weeks post-STZ treatment fasting blood glucose concentrations were 14.1±1.1 mmol/L. However, 4 out of 9 Minipigs showed persistent reductions in feed intake and were excluded from the study. Eight weeks post-STZ treatment, at the start of the Bitter gourd trials, fasting plasma glucose concentrations were 9.8±2.2 mmol/L.

Strategy 3 (aim to induce overt diabetes): two injections of STZ (1 g on the first day and 2 g on the second day) were given to 4 Minipigs. These 4 Minipigs were added to the study from trial 5 onwards. Mean baseline 18-h fasting blood glucose concentrations were 2.5±0.2 mmol/L. Three weeks post-STZ treatment fasting blood glucose concentrations were 14.4±3.1 mmol/L. No reductions in feed intake were observed. Eight weeks post-STZ treatment, at the start of the Bitter gourd trials, fasting plasma glucose concentrations were 9.6±1.8 mmol/L.

One obese Minipig was used as non-STZ treated reference.

In vivo testing of Bitter gourd and timeline

Two to 3 months after the induction of diabetes, pigs were used to investigate the metabolic effects of Bitter gourd. First, the pigs were habituated to the taste of Bitter gourd (fruit or stems-leaves) and of grass over a period of three weeks. Thereafter testing of the various cultivars of Bitter gourd was started. The cross-over design per trial is represented schematically in Fig 1. At the start of each period, the daily obesogenic meals (500 g) were supplemented with stepwise increasing doses of 5, 10, 15 and 20 g of test materials. To warrant complete uptake of the obesogenic diet and the supplement, the obesogenic pellets were moisturized with 100 mL water prior administration of the dry supplements to promote sticking of the supplement to the pellets.

Fig 1. Cross-over design.

Fig 1

Half of the pigs (group 1) received Bitter gourd during the first period of 3 weeks; the other half of the pigs (group 2) received grass (control) first.

Ten trials were conducted, each trial lasting six weeks, in consecutive order:

Trial 1: Bitter gourd fruit (cultivar “Wild-type”) versus grass

Trial 2: Bitter gourd fruit (cultivar “HMT 242”) versus grass

Trial 3: Bitter gourd fruit (cultivar “Palee”) versus grass

Trial 4: Bitter gourd fruit (cultivar “Good healthy”) versus grass

Trial 5: Bitter gourd stems and leaves (cultivar “Wild-type”) versus grass

Trial 6: Bitter gourd stems and leaves (cultivar “Bilai”) versus grass

Trial 7: Bitter gourd fruit (cultivar “Bilai”) versus grass

Trial 8: Bitter gourd fruit (mix of trials 1,2,3,4,7 for average Bitter gourd effect) versus no supplement

Trial 9: Bitter Gourd stems and leaves (cultivar “Palee”) versus no supplement

Trial 10: Metformin (3 g per day, maximum human dose) versus no supplement. Metformin is the most prescribed drug for the treatment of type 2 diabetes [20].

Each individual pig was followed-up per 3-week period comprising the following measurements and techniques: 1) daily food intake, 2) 3-weekly body weight, 3) at week 2, an 18-h fasting blood sample (droplet of blood) by ear vein puncture for the measurement of blood glucose, 4) at week 3, an 18-h fasting blood sample (20 mL) by puncture of the jugular vein for measurement of various parameters.

Blood and plasma analyses

A droplet of blood was obtained from the ear vein by puncture and was analysed for glucose concentration on a blood glucose meter (On Call Extra, ACON Laboratories, San Diego, CA, USA). Larger blood samples were obtained from the jugular vein after transient sedation of the Minipigs, quickly induced by inhalation of 4% Sevoflurane (Abbott) combined with 40% oxygen and nitrous oxide via a nose-mouth cap. Both 10 mL of EDTA and 10 mL of heparin blood were collected (BD vacutainer systems, Plymouth, UK). In fresh heparin blood, blood glucose, ketones, total cholesterol, HDL, LDL and triglyceride concentrations were measured on a blood glucose meter (On Call Extra, ACON Laboratories), on a blood ketone meter (On Call Extra, ACON Laboratories) and on a Mission Cholesterol Meter (ACON Laboratories). The EDTA and remaining heparin blood samples were centrifuged at 4000 rpm for 10 minutes at 4°C in a Rotina 35R, typ 1710 (Hettich Centrifugen, D78532 Tuttingeu) and 1 mL aliquots of plasma were stored at -80°C. Plasma insulin concentrations were measured on a porcine insulin ELISA kit (Mercodia, Uppsala, Sweden). Plasma fructosamine concentrations were measured using a nitroblue tetrazolium colometric assay (fructosamine glycated products, Abcam, Cambridge, UK). Plasma total protein concentrations were measured using the colometric Bradford assay (Abcam, Cambridge, UK). All measurements were performed in duplicate.

Chemical profiling of Bitter gourd fruits based on LC-MS, GC-MS and HPTLC

The dried powdered samples of Bitter gourd fruit from the cultivars Wild-type, HTM 242, Palee, Good healthy and Bilai (trials 1,2,3,4 and 7) were studied for the chemical composition based on several extracts and technologies: Gas Chromatography-mass (GC-MS) spectrometry analysis, high performance thin layer chromatography (HPTLC) and Liquid chromatography–mass spectrometry (LC-MS) for targeted analysis.

The extracts for the GC/MS analysis were prepared using MeOH and n-hexane. For MeOH: Extract 30 mg of powder (15 min ultrasonication) with 1 mL of MeOH and aliquot by 100 μL. Remove the solvent with speed vacuum, take one of the aliquot and add 100 μL of pyridine containing 1 mg/mL of methyl palmitate, Add 100 μL of BSTFA with 1% TMCS and react for 60 min at 80°C in a heating block. For n-hexane: 30 mg of dried powder in 1.0 mL of hexane containing 0.5 mg of methyl palmitate, (15 min ultrasonication) and Centrifugation (10 min), Take 200 μL from the supernatant for the analysis. The extract for HPTLC was prepared as follows: 30 mg of dried powder in 1.0 mL of acetone:n-hexane (1:1) extraction and n-hexane extraction and centrifugation.

The samples were analyzed by a 7890A gas chromatograph equipped with a 7693 automatic sampler and a 5975C single quadrupole detector (Agilent, Folsom, CA, USA). Samples were separated on a DB-5 GC column (30 m x 0.25 mm, 0.25 μm film, J&W Science, Folsom, CA, USA) and eluted with He (99.9% purity) as a carrier gas at a flow rate of 1.5 mL.min-1. The oven temperature was programmed as follows: after an initial hold at 60°C for 1 min, temperature was increased at 7°C/min to 290°C and held for 5 min, then increased to 310°C at 5°C /min and held for a further 3 min. The injector was set at 280°C and 1 μL of the sample was injected in splitless mode. The interface temperature was 280°C, and the ion source and quadrupole temperature were 230°C and 150°C, respectively. The ionization energy in EI mode was 70 eV. Compounds were identified by comparison of their retention times and ion spectra with those of the pure compounds. Data was processed using Mass Hunter (B.07, Agilent), AMDIS (V. 2.63, Agilent), and MS search (V. 2.0, Agilent). Compounds were identified using NIST MS library (version 2008).

The metabolites of Bitter gourd were further analysed by high performance thin layer chromatography (HPTLC). HPTLC chromatographic separation was performed on 20 x 10 cm HPTLC silica gel F254 plates (Merck, Darmstadt, Germany) and samples were applied using an automatic Thin Layer Chromatography (TLC) sampler (CAMAG, Muttenz, Switzerland). Sixty mg of samples were extracted with 1.0 mL of n-hexane, and 15 μL of these solutions were applied on the TLC plate. A saturation time of 20 min was set for all chromatographic separations and the solvent migration distance spanned 85 mm from the application point. After the development with a mixture of petroleum ether–acetone–cyclohexane–ethyl acetate–ethanol (60:10:16:10:6), the dried plates were observed under 254 nm and sprayed with NP-PEG [Natural Product Reagent (1% diphenylboryloxyethylamine in MeOH) and polyethylene glycol 4000 (5% polyethylene glycol 4000 in EtOH)]. The plate images were recorded using a TLC visualizer (CAMAG) under 366 nm UV light.

The samples were analysed using liquid chromatography mass spectrometry (LC-MS) using a UHPLC-DAD-QTOF, Thermo Scientific (Dreieich, Germany) UltiMate 3000 system coupled to a Bruker (Bremen, Germany) OTOF-Q II spectrometer with electrospray ionization (ESI). Thirty mg of dried and powdered samples were ultrasonicated for 20 min with 1 mL of 80:20 methanol:water and centrifuged for 20 min to obtain a clear supernatant (13000 rpm). The samples were filtered by 0.2 mm membrane filter. The separation was performed on a Waters C18 column (2.1 x 100 mm, 2.1 μm). The metabolites were eluted at a flow rate of 0.3 mL/min with a gradient of 0.1% of formic acid in water (A) and 0.1% of formic acid in acetonitrile (B) of 10%-100% B in 30 minutes maintained for 5 minutes. The column temperature was assessed at 40°C. The volume of injection was 2 μL. The mass spectrometer parameters were set as follows: nebulizer gas 2.0 bar, drying gas 10.0 mL/min, temperature 250°C, capillary voltage 3500 V. The mass spectrometer was operated in positive mode with a scan range of 100–1650 m/z, and sodium formate was used as a calibrant.

Statistical and data analyses

Per trial, data were analysed by the parametric two-sided Student’s T-test based on paired samples (within subject, cross-over design for test-item versus control) for all obese pigs combined; for mildly diabetic obese pigs only (pigs from strategy 1) or for overtly diabetic pigs only (pigs from strategies 2 and 3). The number of pigs available per strategy group and per trial varied among trials depending on the occurrence of incomplete meal intake or any missing blood samples. Insulin resistance was estimated by a derivative of the HOMA-index [21] being blood glucose x plasma insulin and plasma fructosamine x plasma insulin concentrations. When plasma protein concentration was affected in a trial, plasma fructosamine concentration was also expressed as plasma fructosamine.protein-1 concentration. When data were not distributed normally, data were analysed by the non-parametric Wilcoxon-test. Individual pigs were excluded from data-analysis when meals were not completely consumed throughout a trial. For Bitter Gourd fruit (trials 1,2,3,4 and 7) the data were pooled per pig to get an indication of the average effect of Bitter Gourd fruit compared to grass. For Bitter Gourd stems and leaves (trials 5 and 6) the data were pooled per pig to get an indication of the average effect of Bitter Gourd stems and leaves compared to grass. Data were expressed as Means±SEM. Effects were considered significant when p<0.05.

For chemical profiling of the dried powdered Bitter Gourd samples, the chemical composition of the samples was expressed as area under the curve per specific compound and compared between cultivars. The obtained LC-MS data was further analyzed by a supervised multivariate data analysis, principal component analysis (PCA), in which dimensions of raw data were reduced one or two principal components (PC) in order to get clustering and to reveal and visualize the systematic variation within these compound profiles.

Data files obtained from the LC–MS/MS analyses were converted to mzXML format using Brucker Daltonics DataAnalysis (version 4.1, Bremen, Germany). The LC-MS/MS data was processed using MZMine2 [22]. To build the feature matrix, mass detection was performed using centroid data. The noise level was set at 10,000 for MS and 100 for MS/MS. The chromatograms were built using the ADAP chromatogram builder [23] with a minimum number of scans of 3, group intensity threshold 1000, minimum highest intensity 10,000 and m/z tolerance of 0.05. Chromatograms were deconvoluted using a baseline cut-off algorithm with the following parameters: minimum peak height of 10,000, peak width range of 0.02–1.00 min, and baseline level of 1000. Chromatograms were deisotoped using an isotopic peak grouper algorithm with an m/z tolerance of 0.05 and retention time tolerance of 0.1 min. The features of each sample were aligned using a join alignment algorithm with the following parameters: 0.05 m/z tolerance and 0.1 min retention time tolerance.

Results

Phenotype of obese Minipigs

During the 60 weeks trial period, the phenotype of mildly diabetic obese Minipigs, overtly diabetic obese Minipigs and an obese Minipig without streptozotocin treatment is shown in Table 3.

Table 3. Phenotype of the obese minipigs during the 60 weeks trial period, measured after 18 hours of fasting.

Blood and plasma data are calculated as the average per animal and subsequently as the mean±SEM per group. One obese minipig is shown as reference.

Mildly diabetic obese minipigs (n = 10) Overtly diabetic obese minipigs (n = 9) Reference non-diabetic obese minipig (n = 1)
Average body weight (kg) 95 80 84
Body weight gain (kg) 1 (+1%) -1 (-1%) 2 (+2%)
Blood glucose (mmol.L-1) 3.4±0.1 8.5±0.3 2.7±0.1
Plasma fructosamine (μmol.L-1) 323±12 583±25 291±12
Plasma insulin (pmol.L-1) 81±4 40±2 111±4
Blood total cholesterol (mmol.L-1) 4.3±0.3 4.4±0.2 3.3±0.3
Blood LDL cholesterol (mmol.L-1) 1.9±0.2 2.0±0.2 0.9±0.1
Blood HDL cholesterol (mmol.L-1) 2.1±0.1 1.9±0.1 2.1±0.1
Blood triglycerides (mmol.L-1) 0.89±0.04 1.29±0.09 0.66±0.04
Blood ketones (mmol.L-1) 0.06±0.02 0.16±0.09 0.09±0.05

1 calculated (LDL = Chol–HDL–(Triglycerides / 2.2)

Trials to study the effect of a test-item compared to control

Blood glucose, ketones, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and plasma fructosamine, protein, insulin and feed intake, body weight were measured in the pigs after three week supplementation with test item compared to control.

Trial 1: Bitter gourd fruit (cultivar “Wild-type”) versus grass

Blood cholesterol concentrations were reduced (P = 0.046) in all obese pigs combined (n = 15) by 14% (from 5.7±0.4 to 4.9±0.4 mmol/L).

Trial 2: Bitter gourd fruit (cultivar “HMT 242”) versus grass

No significant effect for any parameter was observed in the pigs.

Trial 3: Bitter gourd fruit (cultivar “Palee”) versus grass

Plasma fructosamine concentrations were reduced (P = 0.03) in all obese pigs combined (n = 15) by 6% (from 450±48 to 423±53 μmol/L). Changes in individual pigs are shown (Fig 2).

Fig 2. Plasma fructosamine concentrations in all individual obese pigs (n = 15) fed Bitter gourd Palee fruit (black circles) or grass as control (open circles) in a paired, within-pig design.

Fig 2

Plasma fructosamine concentrations were reduced (P = 0.03) by Palee fruit.

Plasma fructosamine concentrations were reduced (P = 0.02) in mildly diabetic obese pigs (n = 9) by 11% (from 349±26 to 309±27 μmol/L) and plasma fructosamine x insulin concentrations, a measure of insulin resistance, were decreased (P = 0.04) by 35%, (from 5201±984 to 3381±565 A.U.), i.e. insulin sensitivity was increased. Changes in individual pigs are shown (Fig 3A and 3B).

Fig 3.

Fig 3

Plasma fructosamine (A) and plasma fructosamine x insulin (B) concentrations in individual mildly diabetic obese pigs (n = 9) fed Bitter gourd Palee fruit (black circles) or grass as control (open circles) in a paired, within-pig design. Plasma fructosamine and plasma fructosamine x insulin were reduced (P = 0.02 and P = 0.04, respectively) by Palee fruit.

No effects were observed in the overtly diabetic obese pigs (n = 5). Blood cholesterol concentrations were reduced (P = 0.04) in all obese pigs combined (n = 15) by 8% (from 4.6±0.3 to 4.2±0.3 mmol/L) and blood LDL concentrations were reduced (P = 0.01) by 15% (from 2.2±0.3 to 1.9±0.2 mmol/L). Body weight increased (P = 0.04) by 0.2% (from 91.8±2.7 to 92.0±2.6 kg) at identical feed intake in all obese pigs combined (n = 15). Measurements and calculations are summarized for all obese pigs combined in Table 4.

Table 4. Trial 3, cultivar Palee fruit Bitter gourd tested in all obese pigs combined (n = 15).
Grass mean Grass SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM Grass 100% Grass SEM Bitter gourd % Bitter gourd SEM P-value
Insulin (pmol.L-1) 77 10 63 8 -14 8 100 13.4 82.0 12.3 0.12
Fructosamine (μmol.L-1) 450 48 423* 53 -27 11 100 10.6 93.8* 12.6 0.03
Fructosamine x insulin(A.U.) 5431 813 4137 532 -1294 619 100 15.0 76.2 12.9 0.06
Protein (g.L-1) 99.7 5.5 99.2 6.4 -0.5 6.2 100 5.5 99.5 6.4 0.94
Glucose ear (mmol.L-1) 5.2 0.9 5.2 1.0 -0.0 0.3 100 17.3 99.4 19.9 0.94
Glucose jugular (mmol.L-1) 4.7 0.7 4.8 0.8 0.1 0.2 100 16.1 103.4 17.2 0.33
Glucose jugular x insulin (HOMA) 50.4 6.5 45.8 6.3 -4.4 6.4 100 12.9 91.0 13.8 0.49
Cholesterol (mmol.L-1) 4.6 0.3 4.2* 0.3 -0.4 0.2 100 6.7 91.5* 6.5 0.04
HDL (mmol.L-1) 1.9 0.1 1.9 0.1 -0.0 0.1 100 3.8 96.4 4.0 0.38
LDL (mmol.L-1) 2.2 0.3 1.9* 0.2 -0.3 0.1 100 12.3 85.1* 11.8 0.01
Triglycerides (mmol.L-1) 0.95 0.06 0.95 0.07 0.00 0.07 100 6.6 100.0 7.7 0.93
Ketones (mmol.L-1) 0.01 0.01 0.05 0.03 0.03 0.04 100 130 500 68 0.35
Body weight (kg) 91.8 2.7 92.0* 2.6 0.3 0.1 100 2.9 100.2* 2.8 0.04
Feed intake (kg.day-1) 0.50 0.00 0.50 0.00 0.00 0.00 100 0.2 100 0.2 0.17

1 calculated (LDL = Chol–HDL–(Triglycerides / 2.2)

*p<0.05 compared to grass. A.U., arbitrary units.

Trial 4: Bitter gourd fruit (cultivar “Good healthy”) versus grass

Plasma fructosamine concentrations were reduced (P = 0.02) in all obese pigs combined (n = 15) by 17% (from 490±50 to 404±48 μmol/L). Changes in individual pigs are shown (Fig 4).

Fig 4. Plasma fructosamine concentrations in all individual obese pigs (n = 15) fed Bitter gourd “Good healthy” fruit (black circles) or grass as control (open circles) in a paired, within-pig design.

Fig 4

Plasma fructosamine concentrations were reduced (P = 0.02) by Good healthy fruit.

Plasma fructosamine concentrations were reduced (P = 0.04) in mildly diabetic obese pigs (n = 8) by 21% (from 384±32 to 303±22 μmol/L) as shown in the lower part of Fig 4. No effects were observed in the overtly diabetic obese pigs (n = 6).

Trial 5: Bitter gourd stems and leaves (cultivar “Wild-type”) versus grass

No significant effect for any parameter was observed in the pigs.

Trial 6: Bitter gourd stems and leaves (cultivar “Bilai”) versus grass

Plasma insulin concentrations were increased (P = 0.03) in all obese pigs combined (n = 20) by 28% (from 53±6 to 67±9 pmol/L) at increased (P = 0.04) plasma fructosamine x plasma insulin concentrations by 33%, a measure of insulin resistance (from 3152±420 to 4190±580 A.U.) and at increased (P = 0.03) blood glucose x plasma insulin concentrations by 22%, the HOMA-index of insulin resistance (from 36±4 to 44±4 A.U.). Changes in individual pigs for plasma insulin concentrations are shown (Fig 5).

Fig 5. Plasma insulin concentrations in all individual obese pigs (n = 20) fed Bitter gourd “Bilai” stems and leaves (black circles) or grass as control (open circles) in a paired, within-pig design.

Fig 5

Plasma insulin concentrations were increased (P = 0.03) by Bilai stems and leaves.

Measurements and calculations are summarized for all obese pigs combined in Table 5.

Table 5. Trial 6, cultivar Bilai stems and leaves of Bitter gourd tested in all obese pigs combined (n = 20).
Grass mean Grass SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM Grass 100% Grass SEM Bitter gourd % Bitter gourd SEM P-value
Insulin (pmol.L-1) 53 6 67* 9 14 6 100 12 128* 14 0.03
Fructosamine (μmol.L-1) 418 54 438 54 20 16 100 13 105 12 0.22
Fructosamine x insulin (A.U.) 3152 420 4190* 580 1038 463 100 13 133* 14 0.04
Protein (g.L-1) 102.8 6.5 103.8 7.2 1.0 3.0 100 6 101 7 0.74
Glucose ear (mmol.L-1) 5.7 0.9 5.7 1.0 0.0 0.2 100 16 100 18 0.96
Glucose jugular (mmol.L-1) 5.0 0.7 5.1 0.7 0.1 0.3 100 15 101 15 0.93
Glucose jugular x insulin (HOMA) 36 4 44* 4 8 3 100 10 122* 10 0.03
Cholesterol (mmol.L-1) 4.2 0.3 4.0 0.2 -0.2 0.2 100 7 95 6 0.24
HDL (mmol.L-1) 1.9 0.1 1.8 0.1 -0.1 0.1 100 4 98 5 0.76
LDL calculated1 (mmol.L-1) 1.9 0.3 1.7 0.2 -0.2 0.1 100 14 90 13 0.12
Triglycerides (mmol.L-1) 0.89 0.09 0.95 0.10 0.06 0.05 100 10 107 11 0.25
Ketones (mmol.L-1) 0.14 0.04 0.09 0.03 -0.05 0.05 100 31 64 29 0.32
Body weight (kg) 86.8 3.4 86.7 3.4 -0.1 0.2 100 4 100 4 0.55
Feed intake (kg.day-1) 0.50 0.00 0.50 0.00 0.00 0.00 100 0.0 100 0.2 0.25

1 calculated (LDL = Chol–HDL–(Triglycerides / 2.2)

*P<0.05 compared to grass. A.U., arbitrary units.

Plasma fructosamine x insulin concentrations, a measure of insulin resistance, were increased (P = 0.047) in mildly diabetic obese pigs (n = 10) by 57% (from 3153±646 to 4933±1002 A.U.).

Trial 7: Bitter gourd fruit (cultivar “Bilai”) versus grass

Plasma protein concentrations were increased (P = 0.049) by 5% in all obese pigs combined (n = 20) (from 96±5 to 101±6 g/L). Plasma fructosamine.protein-1 concentrations were reduced (P = 0.04) by 17% in mildly diabetic obese pigs (n = 10) (from 3.4±0.6 to 2.8±0.4 μmol/g). Blood cholesterol concentrations were increased (P = 0.01) by 19% in mildly diabetic obese pigs (n = 10) (from 4.9±0.4 to 5.8±0.5 mmol/L) and blood LDL concentrations were increased (P = 0.01) by 44% (from 2.0±0.3 to 2.9±0.4 mmol/L).

Pooled effects of trials 1,2,3,4 and 7. Pooled data per pig contain at least 4 out of 5 trials due to incidental incomplete meal intake or a missing blood sample. Plasma fructosamine concentrations were reduced (P = 0.002) in all obese pigs combined (n = 16) by 6% (from 434±42 to 409±43 μmol/L). Plasma fructosamine concentrations were reduced (P = 0.013) in mildly diabetic obese pigs (n = 10) by 9% (from 354±21 to 324±19 μmol/L). Plasma fructosamine concentrations were reduced (P = 0.031) in overtly diabetic obese pigs (n = 5) by 3% (from 615±82 to 599±115 μmol/L). Changes in individual pigs for plasma fructosamine concentrations are shown in S1 Fig.

Trial 8: Reference trial to study the effect of mixed varieties of Bitter gourd fruit compared to “no addition of grass”

Bitter gourd fruit (mix of Wild-type, HMT242, Palee, Good-healthy and Bilai, each 20%) versus no supplement revealed no significant effect for any parameter in the pigs.

Plasma fructosamine concentrations of trials 1,2,3,4,7 and 8 for mildly diabetic obese Minipigs are shown in Table 6. All trials show a numerical or significant reduction in plasma fructosamine concentrations by Bitter gourd fruit.

Table 6. Plasma fructosamine concentrations (μmol.L-1) after 18 hours of fasting in mildly diabetic obese Minipigs fed the dried powdered fruits of 5 different Bitter gourd cultivars (trials 1, 2, 3, 4, 7 and 8) compared to grass (upper panel) or compared to none (no addition) (lower panel).
Grass mean Grass SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM Grass 100% Grass SEM Bitter gourd % Bitter gourd SEM P-value
Wild-type fruit 388 30 380 36 -8 18 100 8 98 9 0.68
Fructosamine
HMT 242 370 27 366 22 -5 20 100 7 99 6 0.81
Fructosamine
Palee 349 26 309* 27 -40 14 100 7 89* 9 0.02
Fructosamine
Good healthy 384 32 303* 22 -81 37 100 9 79* 7 0.04
Fructosamine
Bilai 297 45 262 33 -35 18 100 15 88 12 0.09
Fructosamine
Pooled data from above 354 21 324* 19 -30 10 100 6 91* 6 0.01
Fructosamine
None mean None SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM None 100% None SEM Bitter gourd % Bitter gourd SEM P-value
Mix of the 5 cultivars 339 46 326 51 -13 23 100 14 96 16 0.60
Fructosamine

*P<0.05 compared to grass or none.

Trial 9: Reference trial to study the effect of Bitter gourd stems and leaves compared to “no addition of grass”

Bitter Gourd stems and leaves (cultivar “Palee”) versus no supplement revealed no significant effect for any parameter in the pigs.

Plasma insulin concentrations of trials using bitter gourd stems and leaves (trials 5,6 and 9) for mildly diabetic obese Minipigs are shown in Table 7. All trials show a numerical or significant increase in plasma insulin concentrations by Bitter gourd stems and leaves.

Table 7. Plasma insulin concentrations (pmol.L-1) after 18 hours of fasting in mildly diabetic obese Minipigs fed the dried powdered stems and leaves of three different Bitter gourd cultivars (trials 5, 6 and 9).
Grass mean Grass SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM Grass 100% Grass SEM Bitter gourd % Bitter gourd SEM P-value
Wild-type fruit 61 12 82 10 21 11 100 19 133 12 0.098
Insulin
Bilai 65 9 88 12 24 11 100 14 136 14 0.06
Insulin
Pooled data from above 62 9 84* 10 22 9 100 15 136* 16 0.03
Insulin
None mean None SEM Bitter gourd mean Bitter gourd SEM Delta mean Delta SEM None 100% None SEM Bitter gourd % Bitter gourd SEM P-value
Palee 83 12 102 19 19 17 100 14 122 18 0.32
Insulin

*P<0.05 compared to grass.

Trial 10: Reference trial to study the effect of metformin compared to “no addition”

Body weight was increased (P = 0.003) in all obese pigs combined (n = 20) by 1% (from 84.0±3.6 to 84.8±3.6 kg) at identical feed intake. Body weight was increased (P = 0.04) in mildly diabetic obese pigs (n = 10) by 0.9% (from 93.7±1.8 to 94.5±1.8 kg) at identical feed intake. Plasma fructosamine concentrations were numerically (from 304±33 to 243±23 μmol/L, -20%) but not significantly affected in mildly diabetic obese pigs (n = 10). Changes in individual pigs for metformin are shown in S2 Fig.

Chemical profiling of Bitter gourd fruits based on diverse analytical platforms

High-Performance Thin Layer Chromatography (HPTLC analysis) of Bitter gourd extracts obtained with different solvents did not reveal differences in β-carotene composition related to in vivo glycemic control. Also, Gas Chromatography–Mass Spectrometry (GC-MS analysis) of methanol crude extracts and of n-hexane extracts of the Bitter gourd samples did not result in the possibility to relate certain compounds or combination of compounds to in vivo glycemic control. However, our Liquid Chromatography–Mass Spectrometry (LC-MS) analysis, which was based on an 80:20 methanol:water extract of the Bitter gourd samples, yielded a more distinct chemical profile, particularly with regard to saponins. Through the quantification of compounds and subsequent Principal Component Analysis (PCA) (S3 Fig), we observed clustering among the fruit samples used for pig trials 3 and 4 (cultivars “Palee” and “Good healthy”), which displayed improved in vivo glycemic control. Interestingly, these clusters were associated with specific peaks in the LC-MS chromatograms, suggesting the presence of cucurbitane triterpenoid glycosides that were highly specific to the Bitter gourd fruit cultivars used in trials 3 and 4. These specific peaks, with retention times around 10.1 min (identified as Karaviloside IX), 11.96 min (identified as Acutoside A), and 16.03 min (identified as Xuedanoside H), as shown in S4 Fig, were notably more abundant in samples from trials 3 and 4 compared to samples from trials 1, 2, and 7 (cultivars Wild-type, HMT 242, and Bilai) (Fig 6).

Fig 6. LC-MS chromatograms of the cucurbitane triterpenoid glycosides from various fruit samples.

Fig 6

From the top to bottom, trial 4,3,2,1,7.

Calculation of the combined peak areas under the curves (AUC) for Xuedanoside H, Acutoside A, and Karaviloside IX showed that these were increased in trial 3 (the cultivar “Palee”) more than 3.9-fold and in trial 4 (the cultivar “Good healthy”) more than 8.9-fold compared to the mean of the other trials (trial 1, 2, and 7, the cultivars Wild-type, HMT 242, and Bilai). AUC’s for Xuedanoside H, Acutoside A, and Karaviloside IX are shown in S1 Table.

These findings suggest that a combination of these specific compounds, rather than a single compound, may be associated with the observed improvement in in vivo glycemic control in trials 3 and 4. The identification of these compounds was accomplished through a rigorous process involving the comparison of their mass-to-charge ratios (m/z) and the fragmentation patterns generated by MS/MS analysis. These data were meticulously matched with established databases, including the Dictionary of Natural Compounds and data from literature [2428].

It is important to underscore that the identification of these compounds was made with a high level of confidence, bolstered by the precise matching of their mass spectra and fragmentation patterns to established reference data. Nevertheless, it remains imperative to acknowledge that further research is essential to unveil the precise mechanisms and interactions of these compounds in relation to glycemic control. This comprehensive understanding will require additional investigations, potentially encompassing bioactivity assays, metabolic studies, and mechanistic experiments, to corroborate their roles in mediating the observed improvements in in vivo glycemic control during trials 3 and 4.

Discussion

The diabetic obese Minipig model used in the present study is characterized by elevated fasting blood glucose concentrations, reduced fasting plasma insulin concentrations, increased plasma fructosamine concentrations and blood ketone concentrations within the normal range, characteristic for obese type 2 diabetes [9]. Of note is that blood glucose concentration compared to plasma glucose concentration is approximately 50% lower in Minipigs because pig blood cells do not contain free glucose [29]. Fasting plasma glucose concentrations in the Minipigs are therefore clearly within the human range (4 to 13 mmol/L, i.e. the normal to diabetic condition) although blood and not plasma glucose was measured in the present study. With respect to dyslipidemia, the mild obesogenic diet fed to the pigs contained 20% sucrose, 13% lard and 0.5% cholesterol leading to a state of mild fasting blood hypercholesteremia, alike mild dyslipidemia in humans (LDL ~2 mmol/L) [30]. Fasting blood triglyceride concentrations in the pigs are within the normal human range (<1.9 mmol/L) [31]. As a consequence, the adult, mildly diabetic, obese Göttingen Minipig is a valuable human-sized translational model to study the mode of action of functional foods on glucose and cholesterol metabolism [8].

This translational study in diabetic obese Minipigs shows that the most effective Bitter gourd fruit cultivars “Palee” and “Good healthy” reduce plasma fructosamine concentrations in mildly diabetic obese subjects in the range of 6–21% without affecting 18-h fasting blood glucose concentrations. Plasma fructosamine concentration is a reflection of mean daily (average of fasting and prandial) blood glucose concentrations over the previous 2 to 3 week time period [32, 33]. This suggests that the beneficial effect of Bitter gourd fruit on glycemic control is mainly related to the prandial and not to the fasting period. Chemical profiling of the most effective Bitter gourd fruit cultivars (Palee and Good healthy) show that these cultivars contain higher compound intensities of the triterpenoids Xuedanoside H, Karaviloside IX and Acutoside A compared to the less effective fruit cultivars (Wild type, HMT242 and Bilai). These triterpenoids have previously been identified in Bitter gourd [2428]. Xuedanoside H is a phenolic glycoside derivate which is known to be a SGLT2 inhibitor [34, 35]. This means that it blocks the activity of the glucose transport protein in the kidney. The result is that Xuedanoside H lowers blood glucose concentrations by increasing the flow of glucose from blood to urine. In fact, a Xuedanoside-like compound is present in the already existing anti-diabetic drug Dapagliflozin, used for the treatment of type-2 diabetic patients [34]. Karaviloside IX is a triterpene which is known to be an α-amylase and α-glucosidase inhibitor [26]. This implies that it blocks enzymes that digest starches in the small intestine. Impaired degradation of starch leads to a lower influx of glucose from the gut to blood, thereby reducing blood glucose concentrations. The anti-diabetic drug Acarbose, used for the treatment of type-2 diabetic patients, has a similar mode of action. Acutoside A is a pentacyclic triterpenoid derived from oleanolic acid with substitution by a 2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl moiety at position O-3. Pentacyclic triterpenes have antioxidant properties and can modulate diabetes by hypoglycemic bioactivity [36]. When looking at the mode of action of Xuedanoside H, Karaviloside IX and Acutoside A on in vivo glycemic control, it seems logic that the beneficial effects of Bitter gourd fruits Palee and Good healthy are mainly related to the prandial phase where food is digested and metabolic glucose fluxes are high. With respect to the cultivar Palee, also a decrease in plasma fructosamine x insulin concentrations was found, being a surrogate index for increased insulin sensitivity, alike the HOMA index (glucose x insulin) [21]. Therefore, the complex mixture of many bioactive components present in Bitter gourd fruit seems to have multiple modes of action to affect glucose metabolism.

When pooling the data from the five tested Bitter gourd fruit cultivars Wild-type, HMT242, Palee, Good healthy and Bilai, a general effect of Bitter gourd fruit on glycemic control is obtained. Pooling the data results in significant effects of Bitter gourd fruit on glycemic control: all obese Minipigs combined show a 6% reduction in plasma fructosamine concentrations. Bitter gourd fruit seems most effective in mildly diabetic obese pigs where a 9% reduction in plasma fructosamine concentrations is observed and in overtly diabetic obese pigs a 3% reduction in plasma fructosamine concentrations is found. These effects seem small but in combination with changes in life style (reduction in food intake and increase in physical activity) and in combination with anti-diabetic medication, the effects may be partly cumulative. Indeed, with respect to mono-therapy using the purified anti-diabetic drug metformin, the mode of action of Bitter gourd fruit seems to be different from metformin. Metformin is known to reduce hepatic glucose production which is the primary contribution to the blood glucose-reducing effect by metformin; however, the complete mechanism of action of metformin is still not fully understood [37, 38]. By contrast, Bitter gourd fruit is known to enhance cellular glucose uptake and inhibit glucose absorption from intestine [1]. Yet, to have proof for the possible additive effects of Bitter gourd and metformin, further studies are needed.

In our mildly diabetic obese pig model, metformin resulted in a numerical but not significant reduction in plasma fructosamine concentrations by 20%. Of note, when excluding an outlier pig (which showed an unexplained increase in plasma fructosamine concentration >50% by metformin), plasma fructosamine concentrations were significantly (P = 0.021) reduced in mildly diabetic pigs by 26% (from 313±35 to 231±22 μmol/L). For reference see S2 Fig. Ineffectiveness of metformin monotherapy in the human diabetic population has been reported to be in the order of 15% [39], which is in line with the present experiment using mildly diabetic obese pigs. In any case, Bitter gourd fruit may further improve glycemic control in mildly diabetic obese subjects when combined with changes in life style and metformin monotherapy.

The small effects of pooled Bitter gourd fruit on glycemic control are illustrated by trial 8, where a mix of the five Bitter gourd cultivars was compared to “no addition” as control. In this trial a numerical (4%) but no significant reduction in plasma fructosamine concentrations by Bitter gourd was detected in mildly diabetic obese pigs. This small numerical reduction in plasma fructosamine may have been caused by the difference in nutritional load between the two pig groups. The Bitter gourd group was fed 520 g of food per day (500 g of pig pellets plus 20 g of dried powdered Bitter gourd) whereas the control group was fed 500 g of pig pellets without supplement. A difference in nutritional load of 4%. When correcting the effect of Bitter gourd by matching the nutritional load, the reduction of plasma fructosamine concentrations would be in the order of 8% (4% + 4%), reflecting the inverse correlation between meal size and glycemic control [40]. The 8% reduction in plasma fructosamine concentrations matches the outcome of the pooled data from trials 1,2,3,4 and 7 which was 9%. A difference in fibre load may also contribute to an effect on plasma fructosamine concentrations. Fibre is known to affect glucose metabolism [41]. There are many different fibre-types so it is hard to predict the net effect of fibre in Bitter gourd or in grass (as control) on glycemia.

The effect of Bitter gourd on diabetic parameters has been studied in many animal trials [13, 5]. Most often the study subjects were rats and mice and they all had streptozotocin- or alloxan-induced diabetes. The extracts of the different parts of Bitter gourd were orally provided to the rats or mice in the form of a powder or juice. The dosage of Bitter gourd used in the different studies ranged from 20 mg.kg-1 BW to 1000 mg.kg-1 BW. Most studies showed a reduction of hyperglycemia in diabetic rodents. In our pig study we used a dose of 20 g of dried powdered Bitter gourd (whole fruit or stems-leaves) per pig per day. The average pig weight was ~85 kg, therefore the dose was an equivalent of ~235 mg.kg-1 BW. Fresh Bitter gourd fruit contains ~6% dry matter and ~94% water. A dose of 20 g of dried powdered Bitter gourd fruit corresponds therefore with ~330 g of fresh Bitter gourd fruit per day. For translational purposes to the human situation, this can be considered as a very high, almost unrealistic amount of vegetable to be consumed by humans. However, the bioactive components of Bitter gourd may also be ingested by a combination of vegetables, supplements, drinks and any other products which have been developed based on Bitter gourd. As long as the bioactive ingredients are maintained, these products might be able to add up to an active dose. The stems and leaves of Bitter gourd contain ~40% dry matter and ~60% water. A dose of 20 g of dried powdered Bitter gourd stems-leaves corresponds therefore with 50 g of fresh Bitter gourd stems-leaves per day. This amount can be consumed by humans or can be used to make tea. Besides, the effect of Bitter gourd in pigs was found after a 3 weeks intervention while in humans one can follow diets for months which could result in a slow but steady progression towards improved markers for diabetes.

The effect of Bitter gourd fruit on blood cholesterol concentrations seems less consistent. The cultivars Wild-type and Palee reduced blood cholesterol concentrations, the cultivars HMT 242 and Good healthy showed no effect and the cultivar Bilai increased blood cholesterol concentrations. The reason for this ambiguous response is unclear but the organic bioactive compounds produced by Bitter gourd fruit are a complex blend of molecules, and the various active components could each have their mode of action on cholesterol metabolism. This underlines that the mode of action of Bitter gourd fruit seems to be cultivar specific.

Bitter gourd fruit cultivars Palee and Good healthy are good candidates to serve as a functional food for improving glycemic control in mildly diabetic obese patients but the stems and leaves do not seem to have a beneficial effect on glycemic control. Stems and leaves induce an elevation in plasma insulin concentrations in the absence of improved blood glucose or plasma fructosamine concentrations. However, stems and leaves may be interesting as supplement in livestock feed. An elevation in plasma insulin concentrations may promote whole body protein anabolism in young growing animals, thereby increasing production and reducing nitrogen excretion [42]. A recent study by us [43] showed that 0.65–1.3% inclusion of Bitter gourd stems and leaves in feed of growing pigs had no effects on plasma insulin and urea concentrations and on pig performance. These inclusion levels of Bitter gourd stems and leaves in feed were however 3-fold to 6-fold lower compared to the present study (4% inclusion level). Any possible beneficial effects of Bitter gourd stems and leaves in Livestock production require further investigation.

Conclusions

This study shows that the Bitter gourd fruits from the Palee and Good healthy cultivar improve daily plasma glucose control in mildly diabetic obese subjects. These cultivars differed from less effective cultivars in their compound intensities of the triterpenoids Xuedanoside H, Karaviloside IX and Acutoside A. Increasing renal urinary glucose excretion (Xuedanoside H), decreasing carbohydrate digestion in the intestine (Karaviloside IX), increasing hypoglycemic bioactivity (Acutoside A) and increasing insulin sensitivity (fructosamine x insulin) might have been the mode of action. Bitter gourd stems and leaves from the Bilai cultivar increase fasting plasma insulin concentrations.

Supporting information

S1 Fig. Pooled plasma fructosamine concentrations in all individual obese pigs (n = 16) fed 4 or 5 different cultivars of Bitter gourd fruit (black circles) or grass as control (open circles) in a paired, within-pig design.

Plasma fructosamine concentrations were reduced (P = 0.002) by pooled fruit.

(TIF)

pone.0298163.s001.tif (89.3KB, tif)
S2 Fig. Plasma fructosamine concentrations in individual mildly diabetic obese pigs (n = 10) supplemented with metformin (black circles) or “no addition” as control (open circles) in a paired, within-pig design.

(TIF)

pone.0298163.s002.tif (97.4KB, tif)
S3 Fig. Score plot of principal of component analysis (PC1/PC2) based on LC-MS data.

(TIF)

pone.0298163.s003.tif (2.2MB, tif)
S4 Fig. The fragmentation spectra of Karaviloside IX, Acutoside A and Xuedanoside H.

(TIF)

pone.0298163.s004.tif (318.8KB, tif)
S1 Table. The individual and combined peak area’s under the curves (AUC in arbitrary units) for Xuedanoside H, Acutoside A and Karaviloside IX in Bitter gourd fruit from trials 1,2,3,4 and 7.

(DOCX)

pone.0298163.s005.docx (13.9KB, docx)
S1 File. Individual pig data, further explanations upon request.

(XLSX)

pone.0298163.s006.xlsx (309.6KB, xlsx)

Acknowledgments

We thank Hans van Diepen for formulation of the experimental diets. Piet van Wikselaar, Dirk Anjema, Bert Beukers, Jacolien van Laar, Sabine van Woudenberg, Ries Verkerk and John Jansen are acknowledged for their excellent biotechnical support. Jinke Oosterhof, Vivian van der Nat and Romy Hendricks provided both intellectual and practical assistance to the project. Rene van Rensen is thanked for obtaining dried and powdered Bitter gourd from Vietnam. Karin Senf and Steef Meewisse are acknowledged for their roles in facilitating the project on Bitter gourd.

List of abbreviations

A.I.

arbitrary units

AUC

area under the curve

D

diabetic

GE

gross energy

SGLT2

glucose transport protein

STZ

streptozotocin

Data Availability

Individual pig data may be found in excel S1 File.xlsx.

Funding Statement

This research project “Green Health Solutions” was financially supported by the European Regional Development Fund of the European Union (KVW-00117), a contribution of the Province Zuid-Holland and municipality Almere and by the KB-34 program “Circular and Climate Neutral society” of Wageningen University and Research (KB-34-009-003). There was no role of the funding bodies in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

References

  • 1.Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian pacific journal of tropical disease. 2013;Apr 1;3(2):93–102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027280/?swcfpc=1. doi: 10.1016/S2222-1808(13)60052-3 [DOI] [Google Scholar]
  • 2.Grover J, Yadav S. Pharmacological actions and potential uses of Momordica charantia: a review. Journal of ethnopharmacology. 2004;93(1), 123–132. doi: 10.1016/j.jep.2004.03.035 [DOI] [PubMed] [Google Scholar]
  • 3.Zhu Y, Dong Y, Qian X, Cui F, Guo Q, Zhou X, et al. Effect of superfine grinding on antidiabetic activity of bitter melon powder. International journal of molecular sciences. 2012;13(11), 14203–14218. doi: 10.3390/ijms131114203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Peter EL, Kasali FM, Deyno S, Mtewa A, Nagendrappa PB, Tolo CU, et al. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. Journal of ethnopharmacology. 2019;231, 311–324. doi: 10.1016/j.jep.2018.10.033 [DOI] [PubMed] [Google Scholar]
  • 5.Peter EL, Mtewa AG, Nagendrappa PB, Kaligirwa A, Sesaazi CD. Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus. Systematic Reviews. 2020;9(1), 1–9. doi: 10.1186/s13643-019-1265-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Roura E, Koopmans SJ, Lallès JP, Le Huerou-Luron I, de Jager N, Schuurman T, et al. Critical review evaluating the pig as a model for human nutritional physiology. Nutr Res Rev. 2016;29: p. 60–90. doi: 10.1017/S0954422416000020 [DOI] [PubMed] [Google Scholar]
  • 7.Gutierrez K, Dicks N, Glanzner W, Agellon L, Bordignon V. Efficacy of the porcine species in biomedical research. Frontiers in Genetics. 2015;6. URL = https://www.frontiersin.org/article/10.3389/fgene.2015.00293. doi: 10.3389/fgene.2015.00293 ISSN = 1664–8021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Koopmans SJ, Schuurman T. Considerations on pig models for appetite, metabolic syndrome and obese type 2 diabetes: From food intake to metabolic disease. Eur J Pharmacol. 2015;759: p. 231–239. doi: 10.1016/j.ejphar.2015.03.044 [DOI] [PubMed] [Google Scholar]
  • 9.Coelho PG, Pippenger B, Tovar N, Koopmans SJ, Plana NM, Graves DT, et al. Effect of obesity or metabolic syndrome and diabetes on osseointegration of dental implants in a miniature swine model: a pilot study. Journal of Oral and Maxillofacial Surgery. 2018;Aug1;76(8):1677–87. doi: 10.1016/j.joms.2018.02.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008;Dec;37(4):811–23. doi: 10.1016/j.ecl.2008.08.005 ; PMCID: PMC2710609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Halford JC, Harrold JA. Satiety-enhancing products for appetite control: science and regulation of functional foods for weight management. Proceedings of the Nutrition Society. 2012;May;71(2):350–62. doi: 10.1017/S0029665112000134 [DOI] [PubMed] [Google Scholar]
  • 12.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412. https://www.research.fsu.edu/media/1876/arrive-guidelines-for-publications.pdf. doi: 10.1371/journal.pbio.1000412 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Christoffersen BO, Grand N, Golozoubova V, Svendsen O, Raun K. Gender-associated differences in metabolic syndrome-related parameters in Göttingen minipigs. Comp Med. 2007;Oct;57(5):493–504. . [PubMed] [Google Scholar]
  • 14.Centraal Veevoeder Bureau 2011, CVB table pigs, Product Board Animal Feed, The Hague, The Netherlands. https://www.cvbdiervoeding.nl/bestand/10741/cvb-feed-table-2021.pdf.ashx.
  • 15.Yuwai KE, Rao KS, Kaluwin C, Jones GP, Rivett DE. Chemical composition of Momordica charantia L. fruits. J. Agric. Food Chem. 1991;39,1762–1763. doi: 10.1021/jf00010a013 [DOI] [Google Scholar]
  • 16.Xiang C, Wu CY, Wang LP. Analysis and utilization of nutrient composition in bitter gourd (Momordica charantia). J. Huazhong Agr Univ. 2000;19,388–390. https://www.cabdirect.org/cabdirect/abstract/20013150139. [Google Scholar]
  • 17.Zhang M, Hettiarachchy NS, Horax R, Chen P, Over KF. Effect of maturity stages and drying methods on the retention of selected nutrients and phytochemicals in Bitter Melon (Momordica charantia). Leaf. J. of Food Sc. 2009;Vol.74 (6), 441–448. doi: 10.1111/j.1750-3841.2009.01222.x [DOI] [PubMed] [Google Scholar]
  • 18.Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs. Effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism. 2006;55:960–971. doi: 10.1016/j.metabol.2006.03.004 [DOI] [PubMed] [Google Scholar]
  • 19.Gerrity RG, Natarajan R, Nadler JL, Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes. 2001;50:1654–65. doi: 10.2337/diabetes.50.7.1654 [DOI] [PubMed] [Google Scholar]
  • 20.Metformin.https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/m/metformine.
  • 21.Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling". Diabetes Care. 2004;27 (6):1487–95. doi: 10.2337/diacare.27.6.1487 [DOI] [PubMed] [Google Scholar]
  • 22.Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC bioinformatics. 2010;Dec;11(1):1–1. doi: 10.1186/1471-2105-11-395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Myers OD, Sumner SJ, Li S, Barnes S, Du X. One step forward for reducing false positive and false negative compound identifications from mass spectrometry metabolomics data: new algorithms for constructing extracted ion chromatograms and detecting chromatographic peaks. Analytical chemistry. 2017;Sep 5;89(17):8696–703. doi: 10.1021/acs.analchem.7b00947 [DOI] [PubMed] [Google Scholar]
  • 24.Jin Y, Zhou X, Yang J, Xu X, Zhang J, Ma G. Bioactive triterpenoid saponins from the tubers of Hemsleya amabilis Diels. Fitoterapia. 2019;Nov 1;139:104404. doi: 10.1016/j.fitote.2019.104404 [DOI] [PubMed] [Google Scholar]
  • 25.Li Z, Chen M, Chen F, Li W, Huang G, Xu X, et al. Cucurbitane triterpenoid entities derived from Hemsleya penxianensis triggered glioma cell apoptosis via ER stress and MAPK signalling cross-talk. Bioorganic Chemistry. 2022;Oct 1;127:106013. doi: 10.1016/j.bioorg.2022.106013 [DOI] [PubMed] [Google Scholar]
  • 26.Perera WH, Shivanagoudra SR, Pérez JL, Kim DM, Sun YK, Jayaprakasha G, et al. Anti-inflammatory, antidiabetic properties and in silico modeling of cucurbitane-type triterpene glycosides from fruits of an Indian cultivar of Momordica charantia L. Molecules. 2021;Feb 16;26(4):1038. doi: 10.3390/molecules26041038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nagao T, Tanaka R, Iwase Y, Hanazono H, Okabe H. Studies on the constituents of Luffa acutangula Roxb. I. Structures of acutosides AG, oleanane-type triterpene saponins isolated from the herb. Chemical and pharmaceutical bulletin. 1991;Mar 25;39(3):599–606. doi: 10.1248/cpb.39.599 [DOI] [PubMed] [Google Scholar]
  • 28.Ul Haq F, Ali A, Khan MN, Shah SM, Kandel RC, Aziz N, et al. Metabolite profiling and quantitation of cucurbitacins in Cucurbitaceae plants by liquid chromatography coupled to tandem mass spectrometry. Scientific Reports. 2019;Nov 5;9(1):15992. doi: 10.1038/s41598-019-52404-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Higgins PJ, Garlick RL, Bunn HF. Glycosylated hemoglobin in human and animal red cells: role of glucose permeability. Diabetes. 1982;Sep1;31(9):743–8. doi: 10.2337/diab.31.9.743 [DOI] [PubMed] [Google Scholar]
  • 30.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018;AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice. [Google Scholar]
  • 31.Jacobsen A, Savji N, Blumenthal R. Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline-American College of Cardiology. Washington, DC: American College of Cardiology. 2019. https://www.acc.org/latest-in-cardiology/articles/2019/01/11/07/39/hypertriglyceridemia-management-according-to-the-2018-aha-acc-guideline. [Google Scholar]
  • 32.Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, et al. Oxidized LDL and fructosamine associated with severity of coronary artery atherosclerosis in insulin resistant pigs fed a high fat/high NaCl diet. PloS one. 2015;Jul 6;10(7):e0132302. doi: 10.1371/journal.pone.0132302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tavares Ribeiro R, Paula Macedo M, Filipe Raposo J. HbA1c, fructosamine, and glycated albumin in the detection of dysglycaemic conditions. Current diabetes reviews. 2016;Mar1;12(1):14–9. https://www.ingentaconnect.com/content/ben/cdr/2016/00000012/00000001/art00005#Refs. doi: 10.2174/1573399811666150701143112 [DOI] [PubMed] [Google Scholar]
  • 34.Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes Metab Syndr Obes. 2019;Oct 14;12:2125–2136. doi: 10.2147/DMSO.S212003 ; PMCID: PMC6799898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne). 2021;Dec 20;8:777861. doi: 10.3389/fmed.2021.777861 ; PMCID: PMC8720766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Liu J, Rajendram R, Zhang L. Chapter 158—Effects of Oleanolic Acid and Maslinic Acid on Glucose and Lipid Metabolism: Implications for the Beneficial Effects of Olive Oil on Health. In book: Olives and Olive Oil in Health and Disease Prevention, Academic Press, Editor(s): Victor R. Preedy, Ronald Ross Watson. 2010;1423–1429, ISBN 9780123744203, doi: 10.1016/B978-0-12-374420-3.00158-3 [DOI] [Google Scholar]
  • 37.Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;Sep;60(9):1577–85. https://link.springer.com/article/10.1007/s00125-017-4342-z. doi: 10.1007/s00125-017-4342-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Zhou J, Massey S, Story D, Li L. Metformin: an old drug with new applications. International journal of molecular sciences. 2018;Oct;19(10):2863. doi: 10.3390/ijms19102863 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Jeon JY, Lee SJ, Lee S, Kim SJ, Han SJ, Kim HJ, et al. Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program. Journal of diabetes investigation. 2018;Sep;9(5):1144–52. doi: 10.1111/jdi.12801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.American Diabetes Association. Postprandial blood glucose. Diabetes care. 2001;Apr 1;24(4):775–8. doi: 10.2337/diacare.24.4.775 [DOI] [PubMed] [Google Scholar]
  • 41.Goff HD, Repin N, Fabek H, El Khoury D, Gidley MJ. Dietary fibre for glycaemia control: Towards a mechanistic understanding. Bioactive carbohydrates and dietary fibre. 2018;Apr 1;14:39–53. [Google Scholar]
  • 42.Tesseraud S, Métayer S, Duchêne S, Bigot K, Grizard J, Dupont J. Regulation of protein metabolism by insulin: value of different approaches and animal models. Domestic animal endocrinology. 2007;Aug;1;33(2):123–42. doi: 10.1016/j.domaniend.2006.06.002 [DOI] [PubMed] [Google Scholar]
  • 43.Guan X, Santos RR, Koopmans SJ, Molist F. Effects of the Inclusion of Dietary Bitter Gourd (Momordica charantia) on the Performance and Carcass Characteristics of Pigs: Potential Application in the Feed Chain. Animals. 2023;Jun 30;13(13):2159. doi: 10.3390/ani13132159 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ahmed E Abdel Moneim

1 Sep 2023

PONE-D-23-02230Momordica charantia fruit reduces plasma fructosamine whereas stems and leaves increase plasma insulin in adult mildly diabetic obese Göttingen MinipigsPLOS ONE

Dear Dr. Koopmans,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 16 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ahmed E. Abdel Moneim

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

3. Please upload a new copy of Figure 6 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

Additional Editor Comments:

I have additional comment as follows:

The authors need to go deeper into the study by investigating the molecular mechanisms behind their findings.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

Reviewer #4: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript represents an interesting study on the effect of Bitter gourd on a range of plasma compounds related to diabetes. The use of the diabetic pig model is highly relevant, and an impressing number of studies have been completed. The rationale for choosing mildly and overtly diabetic obese minipigs is missing and a group of obese non-diabetic minipigs would have been interesting as a control group. The chemical profiling of the Bitter gourd fruits is very interesting, however, the description of the methods is insufficient and the level of identification of the triterpenoids is not described. As these results are very interesting and the compounds are contributing to elucidating the mode of action of Bitter gourd, this should be given more focus – in the Introduction as well.

Specific comments:

Line Comment

39 How was this confirmed. This statement is unclear.

75 Which compounds? Mode of action?

Table 1 “Soja hulls RC 320-360” – is this a brand? Or what’s the reason for the name?

144 Was stems and leaves not available for all cultivars?

Table 2 Please define “Crude fiber and non-starch polysaccharides” – maybe it should be including non-starch polysaccharides?

Table 2 Analyzed nutrient composition would have been better.

242 What’s the rationale for using Metformin?

272 How were the metabolites extracted?

273 No description of the GC-MS analysis.

319-321 Very short description, a bit more details would be nice. PCA-analysis?

331 Data could be presented in a table

Table 3 Please add that it is for all pigs – and the number of pigs per treatment.

Table 4 Same as for Table 3.

455 Why against “no addition of grass”?

500 What is meant by “a more characteristic chemical pattern”? Please clarify.

502 I don’t understand the interpretation of Figure 6. In my view trial 2 is very close to trial 3 and 4.

Figure 6 could be exchanged for Supporting Figure S3, which is far more interesting.

505 What is meant by “This classification”?

514 The details on this analysis are missing in Materials and methods.

518 How were the triterpenoids identified? Authentic standards, fragmentation pattern ….? What is the level of identification?

Table 7 Move to supplementary material.

551 Has these triterpenoids previously been identified in Bitter gourd?

560 Please reformulate this sentence.

581-584 Very speculative – reformulate or provide evidence.

590-593 Why wasn’t this pig excluded?

597-598 Speculation.

605 Could the difference in dietary fiber play a role?

607-608 Can these percentages be added in this way?

619 Were there any comparable effects? Discuss the animal models.

645-648 This is very speculative.

650-664 This section could be moved to the beginning of the Discussion.

Reviewer #2: 119 Why did you choose female pigs?

Are the females pregnant or nulliparous?

This choice should be justified

Laboratory animals, especially females, are more sensitive than males and when females are pregnant or nulliparous, the tests may be influenced by these physiological characteristics. These are some of the reasons why it is important to specify the physiological characteristics of the animals tested

304 It should be remembered that diabetes is not limited to the measurement of blood sugar but also to the measurement of triglycerides which are made up of lipids and therefore form fat. As it happens, we can know that in the Krebs cycle, there is a gluconeogenesis, which form glucose from non-carbohydrate elements. The fat that is formed as a reserve is transformed and takes on the connotation of sugar ready to be used by the brain to continue feeding the body in case of prolonged fasting. In summary, a diabetic needs to control both sugar and membrane lipids and to have at his disposal foods such as bitter gourd to slow down the frequent desire of appetite in order to control the two parameters mentioned above.

I congratulate the authors for the quality and the scope of the study which reinforces the endogenous knowledge and moreover relieves the patients of this chronic pathology which gnaws rich and poor as well in Africa in Europe etc..

Reviewer #3: Here are some suggestions to improve the quality of the manuscript

Abstract

1. The methodology needs to be rephrased for clarity. How many groups? What did each group receive?

2. Did you give the same treatment to both mildly and overtly diabetic obese minipigs?

3. How many cultivars of bitter gourd did you use?

Methods

1. Line 119, what is the total number of pigs used? How many are diabetic?

2. Lines 231-242, why did you exclude cultivars HMT 242, Good health, and Palee versus grass for better gourd stems and leaves?

3. How many pigs did you use in each trial?

4. Why did you choose grass as the control diet for some trials and no supplement as a control for other trials?

5. Line 272, did you use a single extract? If no, state all the extracts used.

6. Did you perform each trial on both mildly and overtly diabetic obese minipigs?

Results

1. Lines 302-321, did you compare the insulin, cholesterol, blood glucose, and fructosamine level between the mildly and overtly diabetic obese minipigs?

2. Lines 332-352, please compare the fructosamine, insulin, cholesterol, LDL, HDL, triglycerides, and ketones between obese minipigs without streptozotocin treatment (control), mildly and overtly diabetic obese minipigs using the significant increase or decrease.

3. Indicate if there are significant changes in all the parameters evaluated between the control and treatment groups in all the trials.

4. Use symbols to indicate significant changes in tables 3-6.

5. The results for glucosamine, blood glucose, and insulin should be presented for all the cultivars.

Reviewer #4: The manuscript entitled “<momordica charantia=""> fruit reduces plasma fructosamine whereas stems and leaves increase plasma insulin in adult mildly diabetic obese Göttingen Minipigs.” has been reviewed. The authors present a very interesting work on the use of Bitter gourd and the potential use as alternative medicine for glucose and obesity control.

The animal study was complex but carefully designed and the authors have a good experience in establishing swine models for metabolic diseases, particularly the diabetic induced minipig model.

The authors have done a good job presenting the results and implications of their findings. However, several of the finds particularly to the compounds which can be related to the positive effects of the Bitter gourd should be better clarified.

Minor comments

Line 31: the term human-sized adult GM is rather confusing. Although it’s understandable what the authors would like to say, that the model of GM is representative of an adult human, human-sized minipig is not fully correct. Please rephrase. Similar for line 83.

Line 42: metabolomics” is too general. One could say “studied by metabolomics phenotying” or “metabolomics profiling”.

Line 550, Line 669: it would more advised to refer to these compounds in term of “compound intensities” rather than concentration since they were not actually quantified using chemical standards.

Major comments on section Section 492: Chemical profiling

Line 499. There is a discrepancy between what is written here and what was presented in the materials and menthods section. Line 499 mentions 80:20 methanol:water whereas in the M&M the LC-MS extractions were done using 100% methanol. Which one is correct?

Please provide more information how extracts were prepared for the LCMS analysis. The authors only mention the extraction solvent used and nothing on the sample preparation.

Line 501: PCA analysis was preformed on the data but there is no mention of how the metabolomics data was extracted, what software was used and how was the data treated before PCA analysis. Please add this information in M&M.

Line 501: Please note that the score plot of the PCA analysis shows that the Sample from trial 2 is also clustering rather close with samples from Trial 4 and Trial 3 and separating from Trial 7 and Trial 1 along the first Principal component (PC1).

Line 501: Is it correct that the authors mention quantification? Perhaps they meant compound identification. Quantification implies the use of standard curves and the use of internal standards in the analysis which is not mentioned in the materials and methods.

Line 518: How was the identification preformed? Was it done by comparison of spectra to that of metabolomics databases ? If so which databases were used?

Please provide in supplemental material the fragmentation spectra of these specific compounds.

Furthermore, the authors mention identification. To which level according to Sumner et al were identified? Level 1 using chemical standards to compare, or only annotations based on similarities to public mass spectra databases.

Please mention this, as it is important to have a better understanding of the level of accuracy in the identification of molecular features using metabolomics. Otherwise wrong conclusions can be drawn because of poor compound annotations.

Sumner LW, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007 Sep;3(3):211-221. doi: 10.1007/s11306-007-0082-2. PMID: 24039616; PMCID: PMC3772505.

Line 513: how was this analysis preformed more “focused”? Please clarify.</momordica>

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Lamine Baba-Moussa

Reviewer #3: Yes: Nathan Isaac Dibal

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 18;19(3):e0298163. doi: 10.1371/journal.pone.0298163.r002

Author response to Decision Letter 0


5 Jan 2024

Response to reviewers and the editor have been implemented in the word file: "response to reviewers".

Attachment

Submitted filename: Response to reviewers.docx

pone.0298163.s007.docx (85.8KB, docx)

Decision Letter 1

Ahmed E Abdel Moneim

22 Jan 2024

Momordica charantia fruit reduces plasma fructosamine whereas stems and leaves increase plasma insulin in adult mildly diabetic obese Göttingen Minipigs

PONE-D-23-02230R1

Dear Dr. Koopmans,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ahmed E. Abdel Moneim

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The have well adressed my comments. The manuscrits could be accepted for publication in curent form.

Reviewer #3: The authors have revised the manuscript as suggested. However, highlighting the revision made with different colors is required for easy identification.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Baba-Moussa Lamine Saïd

Reviewer #3: Yes: Nathan Isaac Dibal

**********

Acceptance letter

Ahmed E Abdel Moneim

6 Mar 2024

PONE-D-23-02230R1

PLOS ONE

Dear Dr. Koopmans,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ahmed E. Abdel Moneim

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Pooled plasma fructosamine concentrations in all individual obese pigs (n = 16) fed 4 or 5 different cultivars of Bitter gourd fruit (black circles) or grass as control (open circles) in a paired, within-pig design.

    Plasma fructosamine concentrations were reduced (P = 0.002) by pooled fruit.

    (TIF)

    pone.0298163.s001.tif (89.3KB, tif)
    S2 Fig. Plasma fructosamine concentrations in individual mildly diabetic obese pigs (n = 10) supplemented with metformin (black circles) or “no addition” as control (open circles) in a paired, within-pig design.

    (TIF)

    pone.0298163.s002.tif (97.4KB, tif)
    S3 Fig. Score plot of principal of component analysis (PC1/PC2) based on LC-MS data.

    (TIF)

    pone.0298163.s003.tif (2.2MB, tif)
    S4 Fig. The fragmentation spectra of Karaviloside IX, Acutoside A and Xuedanoside H.

    (TIF)

    pone.0298163.s004.tif (318.8KB, tif)
    S1 Table. The individual and combined peak area’s under the curves (AUC in arbitrary units) for Xuedanoside H, Acutoside A and Karaviloside IX in Bitter gourd fruit from trials 1,2,3,4 and 7.

    (DOCX)

    pone.0298163.s005.docx (13.9KB, docx)
    S1 File. Individual pig data, further explanations upon request.

    (XLSX)

    pone.0298163.s006.xlsx (309.6KB, xlsx)
    Attachment

    Submitted filename: Response to reviewers.docx

    pone.0298163.s007.docx (85.8KB, docx)

    Data Availability Statement

    Individual pig data may be found in excel S1 File.xlsx.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES